Template:Ion channel modulators: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
en>Informationdude420 Added Suzetrigine to list of analgesic sodium channel blockers |
||
| Line 1: | Line 1: | ||
{{ | {{#invoke:navbox|navbox | ||
| name = Ion channel modulators | | name = Ion channel modulators | ||
| title = [[Channel modulator|Ion channel modulator]]s | | title = [[Channel modulator|Ion channel modulator]]s | ||
| Line 7: | Line 7: | ||
| group1 = [[Calcium channel|Calcium]] | | group1 = [[Calcium channel|Calcium]] | ||
| list1 = {{ | | list1 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| group1 = {{abbrlink|VDCCs|Voltage-dependent calcium channels}} | | group1 = {{abbrlink|VDCCs|Voltage-dependent calcium channels}} | ||
| list1 = {{ | | list1 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| Line 195: | Line 195: | ||
| group2 = [[Potassium channel|Potassium]] | | group2 = [[Potassium channel|Potassium]] | ||
| list2 = {{ | | list2 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| group1 = {{abbrlink|VGKCs|Voltage-gated potassium channels}} | | group1 = {{abbrlink|VGKCs|Voltage-gated potassium channels}} | ||
| list1 = {{ | | list1 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| Line 297: | Line 297: | ||
| group2 = {{abbrlink|IRKs|Inwardly rectifying potassium channel}} | | group2 = {{abbrlink|IRKs|Inwardly rectifying potassium channel}} | ||
| list2 = {{ | | list2 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| Line 323: | Line 323: | ||
* [[Tolbutamide]] | * [[Tolbutamide]] | ||
* '''{{abbrlink|GIRK|G protein-coupled inwardly | * '''{{abbrlink|GIRK|G protein-coupled inwardly rectifying potassium channel}}-specific:''' [[Barium]] | ||
* [[Caramiphen]] | * [[Caramiphen]] | ||
* [[Cloperastine]] | * [[Cloperastine]] | ||
| Line 343: | Line 343: | ||
* [[Mazokalim]] | * [[Mazokalim]] | ||
* [[Minoxidil]] | * [[Minoxidil]] | ||
* [[Minoxidil sulfate]] | |||
* [[Naminidil]] | * [[Naminidil]] | ||
* [[Nicorandil]] | * [[Nicorandil]] | ||
| Line 349: | Line 350: | ||
* [[Sarakalim]] | * [[Sarakalim]] | ||
* '''{{abbrlink|GIRK|G protein-coupled inwardly | * '''{{abbrlink|GIRK|G protein-coupled inwardly rectifying potassium channel}}-specific:''' [[ML-297|ML-297 (VU0456810)]] | ||
}} | }} | ||
| group3 = {{abbrlink|K<sub>Ca</sub>|Calcium-activated potassium channel}} | | group3 = {{abbrlink|K<sub>Ca</sub>|Calcium-activated potassium channel}} | ||
| list3 = {{ | | list3 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| Line 375: | Line 376: | ||
| group4 = {{abbrlink|K2Ps|Tandem pore domain potassium channel}} | | group4 = {{abbrlink|K2Ps|Tandem pore domain potassium channel}} | ||
| list4 = {{ | | list4 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| Line 395: | Line 396: | ||
| group3 = [[Sodium channel|Sodium]] | | group3 = [[Sodium channel|Sodium]] | ||
| list3 = {{ | | list3 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| group1 = {{abbrlink|VGSCs|Voltage-gated sodium channels}} | | group1 = {{abbrlink|VGSCs|Voltage-gated sodium channels}} | ||
| list1 = {{ | | list1 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| Line 435: | Line 436: | ||
* [[Ethotoin]] | * [[Ethotoin]] | ||
* [[Fosphenytoin]] | * [[Fosphenytoin]] | ||
* [[Lamotrigine]] | |||
* [[Lacosamide]] | * [[Lacosamide]] | ||
* [[Licarbazepine]] | * [[Licarbazepine]] | ||
| Line 494: | Line 496: | ||
* [[Raxatrigine]] | * [[Raxatrigine]] | ||
* [[RG7893|RG7893 (GDC-0287)]] | * [[RG7893|RG7893 (GDC-0287)]] | ||
* [[Suzetrigine]] | |||
* ''Toxins:'' [[Conotoxin]]s | * ''Toxins:'' [[Conotoxin]]s | ||
| Line 519: | Line 522: | ||
| group2 = {{abbrlink|ENaC|Epithelial sodium channel}} | | group2 = {{abbrlink|ENaC|Epithelial sodium channel}} | ||
| list2 = {{ | | list2 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| Line 536: | Line 539: | ||
| group3 = {{abbrlink|ASICs|Acid-sensing ion channel}} | | group3 = {{abbrlink|ASICs|Acid-sensing ion channel}} | ||
| list3 = {{ | | list3 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| Line 556: | Line 559: | ||
| group4 = [[Chloride channel|Chloride]] | | group4 = [[Chloride channel|Chloride]] | ||
| list4 = {{ | | list4 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| group1 ={{abbrlink|CaCCs|Calcium-activated chloride channel}} | | group1 ={{abbrlink|CaCCs|Calcium-activated chloride channel}} | ||
| list1 = {{ | | list1 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| Line 585: | Line 588: | ||
| group2 = {{abbrlink|CFTR|Cystic fibrosis transmembrane conductance regulator}} | | group2 = {{abbrlink|CFTR|Cystic fibrosis transmembrane conductance regulator}} | ||
| list2 = {{ | | list2 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| Line 607: | Line 610: | ||
| group3 = Unsorted | | group3 = Unsorted | ||
| list3 = {{ | | list3 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| Line 631: | Line 634: | ||
| group5 = Others | | group5 = Others | ||
| list5 = {{ | | list5 = {{#invoke:navbox|navbox|child | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| groupwidth = 5em; | | groupwidth = 5em; | ||
| Line 651: | Line 654: | ||
[[Category:Drug templates by receptor, channel, or pump]] | [[Category:Drug templates by receptor, channel, or pump]] | ||
</noinclude> | </noinclude> | ||
